Literature DB >> 19918902

T2 relaxation time abnormalities in bipolar disorder and schizophrenia.

Dost Ongür1, Andrew P Prescot, J Eric Jensen, Elizabeth D Rouse, Bruce M Cohen, Perry F Renshaw, David P Olson.   

Abstract

There are substantial abnormalities in the number, density, and size of cortical neurons and glial cells in bipolar disorder and schizophrenia. Because molecule-microenvironment interactions modulate metabolite signals characteristics, these cellular abnormalities may impact transverse (T2) relaxation times. We measured T2 relaxation times for three intracellular metabolites (N-acetylaspartate+N-acetylaspartylglutamate, creatine+phosphocreatine, and choline-containing compounds) in the anterior cingulate cortex and parieto-occipital cortex from 20 healthy subjects, 15 patients with bipolar disorder, and 15 patients with schizophrenia at 4 T. Spectra used in T2 quantification were collected from 8-cc voxels with varying echo times (30 to 500 ms, in 10-ms steps). Both bipolar disorder and schizophrenia groups had numerically shorter T2 relaxation times than the healthy subjects group in both regions; these differences reached statistical significance for creatine+phosphocreatine and choline-containing compounds in bipolar disorder and for choline-containing compounds in schizophrenia. Metabolite T2 relaxation time shortening is consistent with reduced cell volumes and altered macromolecule structures, and with prolonged water T2 relaxation times reported in bipolar disorder and schizophrenia. These findings suggest that metabolite concentrations reported in magnetic resonance spectroscopy studies of psychiatric conditions may be confounded by T2 relaxation and highlight the importance of measuring and correcting for this variable. Copyright (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19918902     DOI: 10.1002/mrm.22148

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  27 in total

Review 1.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 2.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

3.  Elevated gamma-aminobutyric acid levels in chronic schizophrenia.

Authors:  Dost Ongür; Andrew P Prescot; Julie McCarthy; Bruce M Cohen; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

4.  Changes in the intracellular microenvironment in the aging human brain.

Authors:  Dinesh K Deelchand; J Riley McCarten; Laura S Hemmy; Edward J Auerbach; Lynn E Eberly; Małgorzata Marjańska
Journal:  Neurobiol Aging       Date:  2020-07-25       Impact factor: 4.673

5.  In vivo T(2) relaxation time measurement with echo-time averaging.

Authors:  Andrew P Prescot; Xianfeng Shi; Changho Choi; Perry F Renshaw
Journal:  NMR Biomed       Date:  2014-05-28       Impact factor: 4.044

6.  Transverse relaxation time constants of the five major metabolites in human brain measured in vivo using LASER and PRESS at 3 T.

Authors:  Dinesh K Deelchand; Edward J Auerbach; Naoharu Kobayashi; Małgorzata Marjańska
Journal:  Magn Reson Med       Date:  2017-07-10       Impact factor: 4.668

7.  Potential clinical impact of multiparametric quantitative MR spectroscopy in neurological disorders: A review and analysis.

Authors:  Ivan I Kirov; Assaf Tal
Journal:  Magn Reson Med       Date:  2019-08-08       Impact factor: 4.668

8.  Simultaneous determination of metabolite concentrations, T1 and T2 relaxation times.

Authors:  Li An; Shizhe Li; Jun Shen
Journal:  Magn Reson Med       Date:  2017-02-05       Impact factor: 4.668

9.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 10.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.